Pharmacological interventions for post-menopausal osteoporosis: An evidence-based approach

Rheumatology

Volumn 39, Issue 12, 2000, Pages 1309-1312

  Compston, J E ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; ESTROGEN; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

ADULT; AGE; AGED; BONE DENSITY; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED MEDICINE; FEMALE; FLUSHING; FRACTURE; GASTROINTESTINAL TOXICITY; HORMONE SUBSTITUTION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; NAUSEA; PARESTHESIA; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RISK; SIDE EFFECT;

EID: 0034509440     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/39.12.1309     Document Type: Editorial

References (33)

1. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
2. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
3. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial
4. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
5. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
6. 3 and calcium to prevent hip fracture in elderly women
7. Treatment of postmenopausal osteoporosis with calcitriol or calcium
8. Calcitriol is not effective in postmenopausal osteoporosis
9. Calcitonin-salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: Three-year interim results of the PROOF study
10. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: Results of the FOSIT study
11. Bone matters: Are density increases necessary to reduce fracture risk
12. Prevention of spinal osteoporosis in oophorectomised women
13. Estrogen replacement therapy 1: A 10-year prospective study in the relationship to osteoporosis
14. Treatment of postmenopausal osteoporosis with transdermal estrogen
15. Risedronate reduces risk of hip fracture in elderly women with osteoporosis
16. Use of cyclical etidronate and prevention of non-vertebral fractures
17. Postmenopausal estrogens protect against fractures of the hip and distal radius: A case control study
18. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogens
19. Menopausal estrogen therapy and hip fractures
20. Hormone replacement therapy and risk of hip fracture: Population based case-control study
21. HRT and Vit D in prevention of non-vertebral fractures in postmenopausal women: A 5 year randomized trial
22. Salmon calcitonin nasal spray (NS-CT) reduces risk of vertebral fracture(s) (VF) in established osteoporosis and has continuous efficacy with prolonged treatment: Accrued 5 year worldwide data of the PROOF study
23. Esophagitis associated with the use of alendronate
24. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
25. The effect of raloxifene on risk of breast cancer in postmenopausal women
26. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
27. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
28. Ups and downs for HRT and heart disease
29. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens
30. Risk of venous thromboembolism in users of hormone replacement therapy
31. Hormone replacement therapy and risk of thromboembolism: Population based case-control study
32. Annual injection of vitamin D and fracture of aged bones
33. Vitamin D supplementation and fracture incidence in elderly persons: A randomized, placebo-controlled clinical trial